Dysregulation of growth factor signaling in human hepatocellular carcinoma

被引：320

作者：

Breuhahn, K. ^{[1
]}

Longerich, T. ^{[1
]}

Schirmacher, P. ^{[1
]}

机构：

[1] Heidelberg Univ, Inst Pathol, D-69120 Heidelberg, Germany

来源：

ONCOGENE | 2006年 / 25卷 / 27期

关键词：

hepatocellular carcinoma; growth factors; signal transduction; liver; tumorigenesis; receptors;

D O I：

10.1038/sj.onc.1209556

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Dysregulation of pleiotropic growth factors, receptors and their downstream signaling pathway components represent a central protumorigenic principle in human hepatocarcinogenesis. Especially the Insulin-like Growth Factor/IGF1 receptor (IGF/IGF-1R), Hepatocyte Growth Factor (HGF/MET), Wingless (Wnt/beta-catenin/FZD), Transforming Growth Factor alpha/Epidermal Growth Factor receptor (TGF alpha/EGFR) and Transforming Growth Factor beta (TGF beta/T beta R) pathways contribute to proliferation, antiapoptosis and invasive behavior of tumor cells. This review focuses on the relevant alterations in these pathways identified in human human hepatocellular carcinomas (HCCs). Resultant functional effects are modulated by multiple cross-talks between the different signaling pathways and additional tumor-relevant factors, such as cyclooxygenase-2 and p53. Several specific strategies are currently under development such as receptor kinase inhibitors, neutralizing antibodies and antagonistic proteins, which may improve the systemic treatment of human HCCs.

引用

页码：3787 / 3800

页数：14

共 281 条

[71]

Gotzmann J, 2002, J CELL SCI, V115, P1189

[72] Growth inhibition of human prostate cancer cells in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice by a ligand-specific antibody to human insulin-like growth factors [J].

Goya, M ;

Miyamoto, S ;

Nagai, K ;

Ohki, Y ;

Nakamura, K ;

Shitara, K ;

Maeda, H ;

Sangai, T ;

Kodama, K ;

Endoh, Y ;

Ishii, G ;

Hasebe, T ;

Yonou, H ;

Hatano, T ;

Ogawa, Y ;

Ochiai, A .

CANCER RESEARCH, 2004, 64 (17) :6252-6258

[73] A novel mechanism for mitogenic signaling via pro-transforming growth factor α within hepatocyte nuclei [J].

Grasl-Kraupp, B ;

Schausberger, E ;

Hufnagl, K ;

Gerner, C ;

Löw-Baselli, A ;

Rossmanith, W ;

Parzefall, W ;

Schulte-Hermann, R .

HEPATOLOGY, 2002, 35 (06) :1372-1380

[74]

Gray SG, 2000, INT J MOL MED, V5, P33

[75]

GRONBORG M, 1993, J BIOL CHEM, V268, P23435

[76]

Guirouilh J, 2000, INT J ONCOL, V17, P777

[77] Expression of hepatocyte growth factor in human hepatocellular carcinoma [J].

Guirouilh, J ;

Le Bail, B ;

Boussarie, L ;

Balabaud, C ;

Bioulac-Sage, P ;

Desmoulière, A ;

Schuppan, D ;

Rosenbaum, J .

JOURNAL OF HEPATOLOGY, 2001, 34 (01) :78-83

[78] Studies of ligand-induced site-specific phosphorylation of epidermal growth factor receptor [J].

Guo, L ;

Kozlosky, CJ ;

Ericsson, LH ;

Daniel, TO ;

Cerretti, DP ;

Johnson, RS .

JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY, 2003, 14 (09) :1022-1031

[79]

Hailey J, 2002, MOL CANCER THER, V1, P1349

[80] A specific inhibitor of TGF-β receptor kinase, SB-431542, as a potent antitumor agent for human cancers [J].

Halder, SK ;

Beauchamp, RD ;

Datta, PK .

NEOPLASIA, 2005, 7 (05) :509-521

← 3 4 5 6 7 8 9 10 11 12 →